Last checked: 6 November 2026. US biotechnology company Rezera has launched the marketing process for a proposed Nasdaq initial public offering. Here are the announced preliminary terms and the risks that matter.
US IPO details at a glance
- Proposed ticker: RZRA
- Exchange: Nasdaq Global Market (proposed)
- Preliminary offer range: $11–$13 per share
- Shares offered: 16,666,667
- Indicative offer value: about $183.3 million–$216.7 million before underwriting costs and any additional shares
- Calendar estimate: 12 November 2026 — subject to change
What does Rezera do?
Rezera is a clinical-stage drug developer focused on inflammatory mechanisms involved in cardiovascular and neurological illnesses. Its lead candidate, ruvonoflast, has completed a mid-stage trial and is being advanced toward later-stage development.
Is the IPO date guaranteed?
No. Public IPO calendars indicate 12 November 2026, but the company’s preliminary prospectus says the offering terms may change. A calendar estimate is not a guarantee of pricing, allocation or first trade.
Key risks to understand
Clinical trials can fail or be delayed; regulators may require more evidence; the business may need additional financing; and share prices can be volatile after listing. Investors should read the risk factors and updated final prospectus.
Sources and verification
Source: Preliminary prospectus report (5 November 2026).
Source: US IPO calendar.
Important investor note
This article is informational only and is not investment advice. US IPOs do not use India’s unofficial IPO grey-market premium (GMP) as an official pricing indicator. Dates, offer sizes, price ranges and tickers may change; verify final terms with the SEC, issuer and exchange.